A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers

Background: Jaktinib is a novel selective janus kinase 1/2 inhibitor. The phase I first-in-human study evaluated the tolerance and pharmacokinetics of jaktinib in healthy Chinese subjects. Methods: A randomized, double-blind, placebo-controlled study were designed. A total of 126 healthy subjects we...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jingrui, Lv, Binhua, Yin, Hewen, Zhu, Xiaoxue, Wei, Haijing, Ding, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849180/
https://www.ncbi.nlm.nih.gov/pubmed/33536914
http://dx.doi.org/10.3389/fphar.2020.604314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849180/
https://www.ncbi.nlm.nih.gov/pubmed/33536914
http://dx.doi.org/10.3389/fphar.2020.604314

Ejemplares similares